Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

(2018) Michael R. Savona et al.   CLINICAL CANCER RESEARCH

Retinoic acid, CYP26, and drug resistance in the stem cell niche

(2017) Salvador Alonso et al.   EXPERIMENTAL HEMATOLOGY

Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study

(2017) J.T. Lear et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas

(2017) Sachin Jain et al.   OncoTargets and Therapy

Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells

(2016) Nobuaki Fukushima et al.   CANCER SCIENCE

Primary cilia are present on human blood and bone marrow cells and mediate Hedgehog signaling

(2016) Mohan Singh et al.   EXPERIMENTAL HEMATOLOGY

Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance

(2016) Salvador Alonso et al.   JOURNAL OF CLINICAL INVESTIGATION

‘Acute myeloid leukemia: a comprehensive review and 2016 update’

(2016) I De Kouchkovsky et al.   Blood Cancer Journal

Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma

(2016) Audrey A. Jacobsen et al.   JAMA Dermatology

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

An update of current treatments for adult acute myeloid leukemia

(2015) H. Dombret et al.   BLOOD

Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia

(2015) Richard M. Stone et al.   JOURNAL OF CLINICAL ONCOLOGY

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia

(2015) Raoul Tibes et al.   Journal of Hematology & Oncology

GLI2 inhibition abrogates human leukemia stem cell dormancy

(2015) Anil Sadarangani et al.   Journal of Translational Medicine

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

(2015) N Daver et al.   LEUKEMIA

Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia

(2015) Yiting Lim et al.   Science Translational Medicine

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study

(2015) Giovanni Martinelli et al.   Lancet Haematology

Abstract 1958: Interrogating hedgehog pathway and smoothened inhibition by PF-04449913 in patient-derived acute myeloid leukemia models

(2015) Amy Jackson-Fisher et al.   CANCER RESEARCH

Abstract 1884: Treatment with Hedgehog inhibitor PF-913 attenuates leukemia-initiation potential in acute myeloid leukemia cells

(2015) Yosuke Minami et al.   CANCER RESEARCH

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

(2014) J. E. Lancet et al.   BLOOD

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

(2013) Sylvain Thépot et al.   AMERICAN JOURNAL OF HEMATOLOGY

Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors

(2013) Allison L. Boyd et al.   EXPERIMENTAL HEMATOLOGY

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study

(2013) Utz Krug et al.   PLoS One

B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1

(2013) H Zhou et al.   Cell Death & Disease

Targeting hedgehog in hematologic malignancy

(2012) D. A. Irvine et al.   BLOOD

Abstract 4504: PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models

(2012) Amy J. Jackson-Fisher et al.   CANCER RESEARCH

Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm—Combined Prospective Analysis by the German AML Intergroup

(2012) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

(2011) Christoph Röllig et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytarabine Dose for Acute Myeloid Leukemia

(2011) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

(2011) Michael J. Munchhof et al.   ACS Medicinal Chemistry Letters

Targeting Hedgehog -- a Cancer Stem Cell Pathway

(2010) A. A. Merchant et al.   CLINICAL CANCER RESEARCH

Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

(2010) John F. Seymour et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Hedgehog signaling maintains chemoresistance in myeloid leukemic cells

(2010) K C S Queiroz et al.   ONCOGENE

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

(2009) Alan K. Burnett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

(2009) Chen Zhao et al.   NATURE

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation

(2008) Christine Dierks et al.   CANCER CELL